Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Eduardo Braun (NPI 1144486309)

Field	Value
Entity Type	Individual
Organization	Eduardo Braun
Address	1668 S Us Highway 421
City	Westville
State	IN
ZIP	46391
Taxonomy	Medical Oncology Physician
NPI Enumerated	August 6, 2008

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider is an infusion-focused medical oncology practice: the top revenue drivers are biologic and immune-oncology drug injections rather than evaluation-and-management or imaging services. The three highest-revenue Medicare codes are J9144 (16K claims, $608.8K, 34.5%), J9299 (19.7K claims, $472.3K, 26.8%), and J9271 (10.6K claims, $424K, 24.0%), which together account for 85.2% of the provider's Medicare revenue and indicate a treatment mix centered on monoclonal antibody and checkpoint inhibitor administration.

Revenue concentration is extremely high on a few drug codes: the top three codes (J9144, J9299, J9271) account for 85.2% of Total Medicare revenue and together represent the vast majority of the provider's $1.8M Medicare lifetime revenue. Outside these three items, remaining codes each contribute only single-digit percentages, underscoring that the business is heavily dependent on repeat administration of a narrow set of high-frequency drugs.

Payer mix is effectively single-payer at present: the provider reports Total Medicare revenue of $1.8M and has no Medicaid billing on file, so the practice appears to serve a Medicare-dominated patient population and would be sensitive to Medicare policy or reimbursement changes. The absence of Medicaid billing suggests limited participation in Medicaid networks or a patient mix that does not generate Medicaid claims.

Competitive standing by code is mixed: for J9144 the provider ranks #79 of 615 nationally (87th percentile) which is a relatively high national rank but is labeled "typical, unremarkable volume" in the data, indicating the provider is a meaningful but not dominant national participant for daratumumab. For J9299 the provider ranks #171 of 505 (66th percentile) and for J9271 ranks #1102 of 1841 (39th percentile), both described as typical, which suggests strong specialization in a few agents without clear dominance across all immune-oncology drugs.

Clinical/operational detail from ancillary codes corroborates an infusion-centric workflow: chemotherapy administration codes such as 96413 (357 claims, $33.2K, 1.9%) and add-on infusion codes like 96417 (105 claims, $4.9K, 0.3%) are present at typical volumes, and supportive medications appear (J0897 denosumab: 5.6K claims, $100.4K, 5.7%). Imaging (78815 and A9552) and higher-level E/M codes are present but account for very small shares of revenue, consistent with a clinic focused primarily on drug delivery.

Notable statistical outlier in office visit billing: 99213 appears as an "extreme outlier, far above typical national volume" with 899 claims and $53K in revenue (3.0% of Medicare revenue), suggesting unusually high volumes of lower-level established patient visits relative to national peers. This pattern could reflect the treatment model (frequent short follow-ups tied to infusion visits) and is worth investigating for operational capacity or coding practice implications.

Tenure is long-standing: the NPI was enumerated 2008-08-06 (~18 years ago), indicating the provider has an established presence and multi-year billing history in Medicare, which supports interpretation of patterns as stable practice behavior rather than a brief or newly opened operation. That tenure, combined with concentrated drug revenue, suggests a sustained infusion practice rather than a transient billing pattern.

Overall, the provider is a specialist infusion operator with heavy reliance on three high-volume oncology drug codes (J9144, J9299, J9271) for $1.8M in Medicare revenue and no Medicaid activity. For payers and competitors, the key implications are concentration risk in a narrow drug set, a Medicare-dependent payer mix, and an atypically high volume of low-level E/M visits (99213) accompanying infusion services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

42 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	16,020	$40	$608.8K
J9299	Injection, nivolumab, 1 mg	19,680	$20	$472.3K
J9271	Injection, pembrolizumab, 1 mg	10,600	$40	$424K
J0897	Injection, denosumab, 1 mg	5,580	$20	$100.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	900	$60	$53K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	360	$90	$33.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	10	$1,060	$13.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	110	$90	$9.8K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	110	$50	$5.6K
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	450	$10	$5K

Showing 1–10 of 42

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 42 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Eduardo Braun — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

42 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	20	11,200	$40	$631.7K
J9299	3	10	21,700	$20	$498.3K
J9144	1	10	12,960	$40	$484.3K
J0897	46	220	2,730	$20	$74.9K
78815	138	140	60	$300	$26.6K
96413	21	120	140	$90	$19.1K
99214	5,409	10,540	110	$80	$15.5K
J3490	28	40	50	$180	$12.8K
J0185	13	20	5,070	$1	$12.5K
74177	417	470	120	$70	$10.6K

Showing 1–10 of 42

Related Providers

Other providers that share a Tax Identification Number (TIN) with Eduardo Braun, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community Care Network Inc	IN	Family Medicine Physician	$0	$33.9M
Ayman Rawda	IL	Pediatrics Physician	$0	$15M
Franciscan Health Crown Point	IN	General Acute Care Hospital	$0	$11.4M
Lake Hospital System Inc	OH	Family Medicine Physician	$0	$6.9M
Michael Blair	IL	Retina Specialist (Ophthalmology) Physician	$3M	$2.6M
Mazen Rachid	IL	Pediatrics Physician	$0	$5.1M
Mohamad Kassar	IN	Hematology & Oncology Physician	$4.7M	$0
Sidney Schechet	MD	Retina Specialist (Ophthalmology) Physician	$4.2M	$0
Ramon Lee	IL	Retina Specialist (Ophthalmology) Physician	$4M	$8.5K
The University Of Chicago Medical Center	IL	General Acute Care Hospital	$0	$3.5M

Eduardo Braun — Billing Profile & Reimbursement Data

Sign up for Eduardo Braun — Billing Profile & Reimbursement Data policy alerts

Eduardo Braun — Billing Profile & Reimbursement Data

Sign up for Eduardo Braun — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Frequently Asked Questions

References